Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822017 | 0.92 | GRM5 (0.85) | GRM5NPC1RAB9A | |
| SCHEMBL15045375 | 0.86 | GRM5 (0.76) | GRM5NPC1RAB9A | |
| SCHEMBL9963860 | 0.86 | GRM5 (0.75) | GRM5NPC1RAB9A | |
| SCHEMBL14176808 | 0.85 | GRM5 (0.74) | GRM5NPC1RAB9A | |
| SCHEMBL9753586 | 0.85 | RAB9A (0.88) | GRM5NPC1RAB9A | |
| SCHEMBL13296220 | 0.85 | GRM5 (0.82) | GRM5NPC1RAB9A | |
| SCHEMBL8555487 | 0.85 | GRM5 (0.74) | GRM5NPC1RAB9A | |
| SCHEMBL23367929 | 0.84 | GRM5 (0.75) | GRM5NPC1RAB9A | |
| SCHEMBL21652196 | 0.82 | GRM5 (0.70) | GRM5NPC1RAB9A | |
| SCHEMBL10806526 | 0.81 | GRM5 (0.68) | GRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| EP-3395795-B1 | MALONONITRILE OXIME ETHER COMPOUND AND USE THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2023-07-19 | — | — | EP | disclosed |
| EP-3822253-A1 | METHOD FOR PREPARING PROPANEDINITRILE OXIME ETHER COMPOUND AND INTERMEDIATE COMPOUND | Shenyang Sinochem Agrochemicals R&D Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
| US-9981043-B2 | Analgesic conjugates | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20150374836-A1 | ANALGESIC CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-12-31 | — | — | US | disclosed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374836-A1 | ANALGESIC CONJUGATES | OPRL1, OPRK1, GRM5 | GRM5 3/4885NPC1 2233/4885RAB9A 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.